Phase I study of combination treatment with PTK 787/ZK 222584 (PTK/ZK) and cetuximab for patients with advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics, and toxicity analysis

被引：0
|
作者：
Langenberg, M. H. [1 ,2 ,3 ]
Witteveen, P. O. [1 ,2 ,3 ]
Lankheet, N. [1 ,2 ,3 ]
Roodhart, J. M. [1 ,2 ,3 ]
Rosing, H. [1 ,2 ,3 ]
Beijnen, J. H. [1 ,2 ,3 ]
Voest, E. E. [1 ,2 ,3 ]
机构：
[1] Univ Med Ctr Utrecht, Utrecht, Netherlands
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Slotervaart Hosp, Amsterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2575
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate.
    Joensuu, H.
    De Braud, F.
    Coco, P.
    De Pas, T.
    Spreafico, C.
    Bono, P.
    Jalava, T.
    Laurent, D.
    Casali, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 527S - 527S
  • [42] Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials
    A Giatromanolaki
    M I Koukourakis
    E Sivridis
    K C Gatter
    T Trarbach
    G Folprecht
    M M Shi
    D Lebwohl
    T Jalava
    D Laurent
    G Meinhardt
    A L Harris
    British Journal of Cancer, 2012, 107 : 1044 - 1050
  • [43] A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer
    Thomas, A
    Morgan, B
    Decatris, A
    Henry, A
    Pfister, C
    Gano, C
    Moss, D
    Laurent, D
    Dugan, M
    Steward, W
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S77 - S77
  • [44] Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222584 on a twice daily schedule in patients with advanced cancer.
    Thomas, A
    Morgan, B
    Rowark, G
    Mason, C
    Henry, A
    Pfister, C
    Moss, D
    Unger, C
    Drevs, J
    O'Byrne, K
    Laurent, D
    Dugan, M
    Steward, W
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3662S - 3663S
  • [45] Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases
    Lee, L
    Sharma, S
    Morgan, B
    Allegrini, P
    Schnell, C
    Brueggen, J
    Cozens, R
    Horsfield, M
    Guenther, C
    Steward, WP
    Drevs, J
    Lebwohl, D
    Wood, J
    McSheehy, PMJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (06) : 761 - 771
  • [46] Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases
    Lucy Lee
    Sunil Sharma
    Bruno Morgan
    Peter Allegrini
    Christian Schnell
    Josef Brueggen
    Robert Cozens
    Mark Horsfield
    Clemens Guenther
    Will P. Steward
    Joachim Drevs
    David Lebwohl
    Jeanette Wood
    Paul M. J. McSheehy
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 761 - 771
  • [47] Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials
    Giatromanolaki, A.
    Koukourakis, M. I.
    Sivridis, E.
    Gatter, K. C.
    Trarbach, T.
    Folprecht, G.
    Shi, M. M.
    Lebwohl, D.
    Jalava, T.
    Laurent, D.
    Meinhardt, G.
    Harris, A. L.
    BRITISH JOURNAL OF CANCER, 2012, 107 (07) : 1044 - 1050
  • [48] A Phase IA, Open-label, Dose-escalating Study of PTK787/ZK 222584 Administered Orally on a Continuous Dosing Schedule in Patients with Advanced Cancer
    Drevs, Joachim
    Medinger, Michael
    Mross, Klaus
    Fuxius, Stefan
    Hennig, Juergen
    Buechert, Martin
    Thomas, Anne
    Unger, Clemens
    Chen, Bee-Lian
    Lebwohl, David
    Laurent, Dirk
    ANTICANCER RESEARCH, 2010, 30 (06) : 2335 - 2339
  • [49] Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome
    G J Roboz
    F J Giles
    A F List
    J E Cortes
    R Carlin
    M Kowalski
    S Bilic
    E Masson
    M Rosamilia
    M W Schuster
    D Laurent
    E J Feldman
    Leukemia, 2006, 20 : 952 - 957
  • [50] Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma
    Brander, Danielle M.
    Beaven, Anne W.
    Gockerman, Jon P.
    Diehl, Louis F.
    Gasparetto, Cristina
    Shea, Thomas C.
    deCastro, Carlos
    Moore, Joseph O.
    Rizzieri, David A.
    BLOOD, 2012, 120 (21)
12345